Synairgen Supercharges R&D With $100m Financing
To Support COVID-19 Study Of Inhaled Beta-Interferon
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
You may also be interested in...
The UK’s biotech sector sees investor interest surge during the pandemic, though IPO levels are still disappointing compared with recent years.
Walmsley has been awarded a damehood in the Queen’s Birthday Honours List. Meanwhile, Synairgen co-founder Holgate is to become a Sir.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.